Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside

Title:Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside

Volume: 13 Issue: 10

Author(s): Z. Liu and F. Wang

Affiliation:

Keywords: Arg-Gly-Asp (RGD), integrin α_vβ₃, molecular imaging, radionuclide therapy, radiotracer, tumor.

Abstract: The cell adhesion molecule integrin α_vβ₃ is an important player in the process of angiogenesis. In the last decades, a series of radiolabeled Arg-Gly-Asp (RGD) peptides targeting integrin α_vβ₃ has been prepared and optimized for positron emission tomography (PET) and single-photon-emission computed tomography (SPECT) imaging of integrin α_vβ₃ expression. Several promising radiotracers have been tested in clinical trials. In this review, we will introduce strategies that have been used to optimize and accelerate RGD radiotracers towards clinical translation; illustrate RGD-based radiotracers that have been investigated in clinical trials; and discuss the other applications of RGD radiotracers aside from tumor detection.

Cite this article as:

Liu Z. and Wang F., Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside, Current Molecular Medicine 2013; 13 (10) . https://dx.doi.org/10.2174/1566524013666131111115347